19th Sep 2014 13:51
Vectura Group plc
Results of the Annual General Meeting held on 19 September 2014
Chippenham, UK, 19 September 2014: Vectura Group plc (LSE: VEC) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed by shareholders.
All resolutions were approved on a poll. The results of the poll are set out below.
Resolution | Total votes for (including discretionary votes)* | % | Total votes against* | % | Total votes cast (excluding votes withheld) | Votes withheld | |
1 | To receive the Annual Report & Accounts | 308,220,299 | 99.73 | 838,734 | 0.27 | 309,059,033 | 0 |
2 | To approve the Remuneration report | 199,895,156 | 65.04 | 107,436,092 | 34.96 | 307,331,248 | 1,727,785 |
3 | To approve the Directors' remuneration policy | 298,881,466 | 98.19 | 5,521,975 | 1.81 | 304,403,441 | 4,655,592 |
4 | To elect Mr Bruno Angelici | 307,402,612 | 99.47 | 1,638,300 | 0.53 | 309,040,912 | 18,121 |
5 | To re-elect Dr Susan Foden | 308,419,055 | 99.81 | 599,053 | 0.19 | 309,018,108 | 40,925 |
6 | To re-elect Dr Trevor Phillips | 307,421,646 | 99.48 | 1,619,266 | 0.52 | 309,040,912 | 18,121 |
7 | To re-elect Dr John Brown | 219,941,664 | 71.47 | 87,796,376 | 28.53 | 307,738,040 | 1,320,993 |
8 | To re-appoint Deloitte LLP as the Company's auditor | 302,879,302 | 98.01 | 6,162,880 | 1.99 | 309,042,182 | 16,851 |
9 | To authorise the Directors to determine the auditor's remuneration | 292,128,550 | 94.53 | 16,910,998 | 5.47 | 309,039,548 | 19,485 |
10 | To approve the Vectura Group plc 2014 Sharesave Scheme | 307,875,225 | 99.62 | 1,176,051 | 0.38 | 309,051,276 | 7,757 |
11 | To authorise the Directors to allot shares | 308,524,485 | 99.83 | 521,148 | 0.17 | 309,045,633 | 13,400 |
12 | To authorise the Directors to allot equity securities for cash | 294,251,546 | 95.21 | 14,796,545 | 4.79 | 309,048,091 | 10,942 |
13 | To authorise the Directors to call general meetings, other than an Annual General Meeting, at not less than 14 clear days' notice | 302,057,351 | 97.73 | 7,000,805 | 2.27 | 309,058,156 | 877 |
*NB: The percentage of votes cast for and against excludes withheld votes.
The Company confirms that copies of all resolutions passed at the Annual General Meeting held earlier today, Friday 19 September 2014, will be submitted to the National Storage Mechanism (NSM) at [email protected] and will shortly be available for viewing.
- Ends -
Enquiries:
Vectura Group plc | +44 (0)1249 667700 |
Chris Blackwell, Chief Executive | |
Paul Oliver, Chief Financial Officer | |
Dr Karl Keegan, Chief Corporate Development Officer | |
FTI Consulting | 44 (0)20 3727 1000 |
Ben Atwell | |
John Dineen |
Notes for Editors:
About Vectura
Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $46 billion worldwide.1
Vectura has eight products marketed by partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has disclosed development collaborations and licence agreements with several pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols and Tianjin KingYork Group Company Limited.
Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com.
References
1 Pharmaview Commercial Landscape Series Respiratory Decision Resources 2013
Related Shares:
VEC.L